Thymic peptide studied in immune-modulation models.
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
Immune-response modulation and host-defense research. In the large TESTS sepsis trial, thymosin alpha-1 did not significantly reduce 28-day mortality; immune mechanisms do not justify a universal immunity-boosting claim.
Clinical findings apply to the studied formulation, population and indication. They do not establish equivalence, safety or therapeutic efficacy of this research product.
PMID: 39814420
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.